Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Aldeyra Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

16 May 2015 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ALDEYRA THERAPEUTICS INC (ALDX-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

25 May 2015 Thomson Reuters Stock Report 10 $25.00

US MARKET ANALYSIS AND FORECAST. 70 PAGE REPORT PUBLISH QUARTERLY. IN EACH REPORT YOU WILL FIND 12-MONTHS FORECASTS ANALYSIS TARGET PRICE VALUATION RATINGS AND CREUDE OIL DEPENDENCE FOR 7396 US STOCKS.

25 May 2015 Pechala's Reports 85 $1,000.00

ALDEXA THERAPEUTICS INC (ALDX) - REPORT FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 May 2015 Pechala's Reports 1 $25.00

ALDEXA THERAPEUTICS INC (ALDX) 12-months forecast

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 May 2015 Pechala's Reports 1 $15.00

ValuEngine Industry Report for Medical-drugs(ALDX)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

21 May 2015 ValuEngine, Inc. 10 $49.00

ValuEngine Rating and Forecast Report for ALDX

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

18 May 2015 ValuEngine, Inc. 10 $25.00

ALDX: 1Q15- After a balance sheet boost, ALDX could further explore NS2 R&D on multiple fronts

This morning, ALDX reported 1Q15 financial results with a net loss of ($2.1MM), vs. Laidlaw and the Street ($2.6MM) estimates...

13 May 2015 Laidlaw & Company 7 $25.00

ALDX: 4Q14: Overall uneventful but 2015 could be transformative as two key clinical results become available

This morning, ALDX reported 4Q14 financial results with a net loss of ($2.2MM), overall in-line with the estimates of Laidlaw...

19 Mar 2015 Laidlaw & Company 7 $25.00

ALDX: NS2 in SLS Phase II study started and the non-infectious anterior uveitis Phase II study to come likely in 2Q15

This morning, ALDX announced the commencement of the NS2 in Sjogren-Larsson Syndrome (SLS) Phase II study, and also indicated...

17 Mar 2015 Laidlaw & Company 7 $25.00